Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 51 peer-reviewed journal articles Updated
Neurology · GMPPB-Related Muscular Dystrophy

GMPPB-Related Muscular Dystrophy: A Patient Guide

At a Glance

GMPPB-related muscular dystrophy is an inherited condition with a wide range of severity, from infant-onset disease to LGMD R19 with later hip and shoulder weakness. Fluctuating weakness, rhabdomyolysis, heart or breathing involvement, and anesthesia risks require individualized, ongoing care.

GMPPB-related muscular dystrophy is a rare genetic condition that affects the strength and stability of the muscles. It belongs to a group of disorders known as alpha-dystroglycanopathies, which occur when the body cannot properly “decorate” certain muscle proteins with essential sugar chains [1]. This process, called glycosylation, is vital because these sugar chains act as a biological glue, anchoring muscle cells to their surroundings and protecting them from damage during movement. In people with this condition, the GMPPB gene does not function correctly, leading to fragile muscle membranes and a wide range of physical symptoms [2].

The condition is inherited in an autosomal recessive pattern, meaning a person must inherit two altered copies of the gene—one from each parent—to be affected [3]. Because the underlying genetic issue can vary in severity, the disease exists on a broad clinical spectrum. On one end is Congenital Muscular Dystrophy (CMD), which appears in infancy and can involve the brain and eyes; on the other is Limb-Girdle Muscular Dystrophy (LGMD R19), which typically appears in adolescence or adulthood and primarily affects the muscles of the hips and shoulders [4].

What Varies From Person to Person
Your genetic test result alone does not perfectly predict your severity. What varies from person to person is immense: some individuals experience severe muscle breakdown, while others have cardiac or respiratory involvement, and some only have mild limb weakness. Always ask your care team which specific features apply to you.

Living with a GMPPB-related disorder requires an understanding that it can involve overlapping features. Unlike many other muscular dystrophies, it often involves a Congenital Myasthenic Syndrome (CMS) overlap, where the communication between nerves and muscles becomes fatigued [5]. This can cause fluctuating weakness that worsens with activity but may improve with rest or specific treatments. Additionally, patients face distinct safety risks, including a vulnerability to rhabdomyolysis (rapid muscle breakdown) and severe risks from certain medications used in general anesthesia [6][7].

Managing this condition is a lifelong process of proactive monitoring and specialized support. Because the heart and breathing muscles can sometimes be involved, regular check-ups with a multidisciplinary team are essential to maintain health and mobility [8]. While the diagnosis is complex, understanding the biological mechanism and the available supportive therapies allows patients and caregivers to navigate the condition with a focus on safety, stability, and quality of life [1].

(Note on terms used in this guide: LGMD = Limb-Girdle Muscular Dystrophy; CMD = Congenital Muscular Dystrophy; CMS = Congenital Myasthenic Syndrome; CK = Creatine Kinase; FVC = Forced Vital Capacity; DXA = Bone Density Scan; RNS = Repetitive Nerve Stimulation.)

In this guide

6 chapters

01

Understanding GMPPB-Related Muscular Dystrophy

Learn how GMPPB-related muscular dystrophy affects muscles, why symptoms vary, how LGMD R19 is diagnosed, and when brain, eye, or nerve features may occur.

02

Managing Symptoms and Recognizing Red Flags

Learn to recognize GMPPB-related limb-girdle muscular dystrophy symptoms, fatigable weakness, rhabdomyolysis signs, and anesthesia risks before surgery.

03

The Diagnostic Journey: Blood Work, Electrical Tests, and Genetics

Learn how GMPPB-related limb-girdle muscular dystrophy is diagnosed with CK, EMG, RNS, muscle biopsy, and genetic testing, including whether variants are in trans.

04

Managing the Condition: Treatment and Supportive Care

Learn how GMPPB-related limb-girdle muscular dystrophy is managed, including CMS medicines, safe exercise, therapy, heart and lung checks, and a sick-day plan.

05

Long-Term Monitoring and Your Surveillance Plan

Learn how GMPPB-related LGMD R19 surveillance checks the heart, lungs, sleep, bones, and mobility, including ECGs, FVC tests, sleep studies, and DXA scans.

06

Building Your Care Team and Preparing for Visits

Learn how to build a GMPPB-related limb-girdle muscular dystrophy care team, prepare records for visits, find experts, and discuss family testing and research.

Common questions in this guide

What is GMPPB-related muscular dystrophy?
GMPPB-related muscular dystrophy is a rare inherited condition caused by changes in both copies of the GMPPB gene. These changes can weaken the connection between muscle cells and their surroundings, so symptoms range from infant-onset congenital muscular dystrophy to later-onset limb-girdle weakness.
What does LGMD R19 mean in GMPPB-related disease?
LGMD R19 is the later-onset limb-girdle form on the GMPPB disease spectrum. It most often causes weakness around the hips and shoulders and may begin in adolescence or adulthood, although severity varies.
Can GMPPB-related disease cause weakness that gets worse with activity?
Yes. Some people have a congenital myasthenic syndrome overlap, in which communication between nerves and muscles becomes fatigued. Weakness may worsen with activity and improve with rest or specific treatments, so discuss fluctuating symptoms with your care team.
Why are anesthesia precautions important with GMPPB-related muscular dystrophy?
Some medications used in general anesthesia can pose severe risks for people with this condition. Ask your care team for a written safety letter describing anesthesia precautions and share it with the anesthesiologist before any procedure.
How is GMPPB-related muscular dystrophy inherited?
It follows an autosomal recessive inheritance pattern, which means a person must receive two altered copies of the GMPPB gene, one from each parent, to be affected. Your care team can explain what the inheritance pattern means for your family.
Can a genetic test predict how severe GMPPB-related disease will be?
Not perfectly. People with GMPPB-related disease can have mild limb weakness, severe muscle breakdown, or heart and breathing involvement, so symptoms and ongoing evaluation are important when planning care.
What monitoring may be needed for GMPPB-related muscular dystrophy?
Because the heart and breathing muscles can sometimes be involved, regular check-ups with a multidisciplinary team are important. Ongoing care can also address mobility, fluctuating weakness, and safety planning based on the person's specific features.

Get notified when new evidence is published on GMPPB-related limb-girdle muscular dystrophy R19.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (8)
  1. 1

    GDP-Mannose Pyrophosphorylase B (GMPPB)-Related Disorders.

    Chompoopong P, Milone M

    Genes 2023; (14(2)) doi:10.3390/genes14020372.

    PMID: 36833299
  2. 2

    GMPPB-congenital disorders of glycosylation associate with decreased enzymatic activity of GMPPB.

    Liu Z, Wang Y, Yang F, et al.

    Molecular biomedicine 2021; (2(1)):13 doi:10.1186/s43556-021-00027-2.

    PMID: 35006422
  3. 3

    Limb-girdle muscular dystrophy due to GMPPB mutations: A case report and comprehensive literature review.

    Sun L, Shen D, Xiong T, et al.

    Bosnian journal of basic medical sciences 2020; (20(2)):275-280 doi:10.17305/bjbms.2019.3992.

    PMID: 30684953
  4. 4

    GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.

    Jensen BS, Willer T, Saade DN, et al.

    Human mutation 2015; (36(12)):1159-63 doi:10.1002/humu.22898.

    PMID: 26310427
  5. 5

    Mutations in GMPPB cause congenital myasthenic syndrome and bridge myasthenic disorders with dystroglycanopathies.

    Belaya K, Rodríguez Cruz PM, Liu WW, et al.

    Brain : a journal of neurology 2015; (138(Pt 9)):2493-504 doi:10.1093/brain/awv185.

    PMID: 26133662
  6. 6

    Mutations in GMPPB Presenting with Pseudometabolic Myopathy.

    Panicucci C, Fiorillo C, Moro F, et al.

    JIMD reports 2018; (38()):23-31 doi:10.1007/8904_2017_25.

    PMID: 28456886
  7. 7

    Anaesthetic management of patients with myopathies.

    Schieren M, Defosse J, Böhmer A, et al.

    European journal of anaesthesiology 2017; (34(10)):641-649 doi:10.1097/EJA.0000000000000672.

    PMID: 28719515
  8. 8

    Limb-Girdle Muscular Dystrophies.

    Liewluck T

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1344-1371 doi:10.1212/cont.0000000000001615.

    PMID: 41037170

This guide is for informational purposes only and does not constitute medical advice. Your care team should interpret your genetic results and create individualized monitoring and anesthesia plans.